PMID- 35480084
OWN - NLM
STAT- MEDLINE
DCOM- 20220429
LR  - 20220716
IS  - 1555-4317 (Electronic)
IS  - 1555-4309 (Print)
IS  - 1555-4309 (Linking)
VI  - 2022
DP  - 2022
TI  - Effects of Serum C-Peptide Level on Blood Lipid and Cardiovascular and 
      Cerebrovascular Injury in Patients with Type 2 Diabetes Mellitus: A 
      Meta-Analysis.
PG  - 6314435
LID - 10.1155/2022/6314435 [doi]
LID - 6314435
AB  - OBJECTIVE: This study aims to investigate the effects of serum C-peptide levels 
      on blood lipid and cardiovascular and cerebrovascular injury in patients with 
      type 2 diabetes mellitus (T2DM). METHODS: China National Knowledge Infrastructure 
      (CNKI), WanFang Data, PubMed, Web of Science, and Embase databases were searched 
      for relevant studies published from January 2010 to June 2021. All retrieved 
      randomized controlled trials that evaluated the effect of serum C-peptide levels 
      on blood lipids or cardiovascular and cerebrovascular injuries in T2DM patients 
      were included in our study. Patients in the included studies were divided into 
      normal C-peptide group (control group) and low C-peptide group (treatment group) 
      according to fasting C-peptide levels. Meta-analysis was performed using 
      Stata16.0. RESULTS: A total of 7 studies were included for the meta-analysis. 
      Compared with the control group, the treatment group was associated with a higher 
      incidence of coronary heart disease (OR = 4.89; 95% CI: 1.13, 21.24; P < 0.05) 
      and cerebral infarction (OR = 3.24; 95% CI: 0.59, 17.66; P < 0.05). In addition, 
      patients in the treatment group had significantly higher levels of total 
      cholesterol (SMD = 0.01; 95% CI: -0.38, 0.39; P < 0.05), triglyceride 
      (SMD = 0.62; 95% CI: 0.24, 1.00; P < 0.05), glycated hemoglobin (SMD = 0.25; 95% 
      CI: -0.50, 1.00; P < 0.05), and low-density lipoprotein cholesterol (SMD = 0.23; 
      95% CI: -0.00, 0.46; P < 0.05). However, there was no significant difference in 
      high-density lipoprotein cholesterol levels between the two groups (SMD = 0.30; 
      95% CI: -0.26, 0.86; P > 0.05). CONCLUSIONS: Low serum C-peptide level 
      significantly increases the incidence of coronary heart disease and cerebral 
      infarction. Additionally, low serum C-peptide increases blood lipid level and 
      promotes lipid deposition. Collectively, low serum C-peptide has a negative 
      impact on the occurrence and development of T2DM and therefore serum C-peptide 
      level needs to be adjusted timely.
CI  - Copyright (c) 2022 Juan Qin et al.
FAU - Qin, Juan
AU  - Qin J
AUID- ORCID: 0000-0002-0826-7514
AD  - Department of Endocrinology and Metabolism, The Fourth People's Hospital of 
      Shenyang, Shenyang 110031, Liaoning, China.
FAU - Sun, Rongli
AU  - Sun R
AD  - Center for Clinical Biological Samples, The First Affiliated Hospital of Jinzhou 
      Medical University, Jinzhou 121000, Liaoning, China.
FAU - Ding, Ding
AU  - Ding D
AD  - Department of Clinical Nutrition, Shengjing Hospital of China Medical University, 
      Shenyang 110000, Liaoning, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20220408
PL  - England
TA  - Contrast Media Mol Imaging
JT  - Contrast media & molecular imaging
JID - 101286760
RN  - 0 (C-Peptide)
RN  - 0 (Lipids)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - C-Peptide
MH  - Cerebral Infarction
MH  - Cholesterol
MH  - *Coronary Disease
MH  - *Diabetes Mellitus, Type 2/epidemiology
MH  - Humans
MH  - Lipids
MH  - Randomized Controlled Trials as Topic
PMC - PMC9012635
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/04/29 06:00
MHDA- 2022/04/30 06:00
PMCR- 2022/04/08
CRDT- 2022/04/28 06:26
PHST- 2021/11/18 00:00 [received]
PHST- 2022/03/07 00:00 [revised]
PHST- 2022/03/17 00:00 [accepted]
PHST- 2022/04/28 06:26 [entrez]
PHST- 2022/04/29 06:00 [pubmed]
PHST- 2022/04/30 06:00 [medline]
PHST- 2022/04/08 00:00 [pmc-release]
AID - 10.1155/2022/6314435 [doi]
PST - epublish
SO  - Contrast Media Mol Imaging. 2022 Apr 8;2022:6314435. doi: 10.1155/2022/6314435. 
      eCollection 2022.